3Yeung CK, Lain LK, Chan HH. The timing of intravenous immunoglobulin therapy in Steven-Johnson Syndrome and toxic epidermal necrolysis [ J ]. Clin Exp Dermatol, 2005, 30 ( 5 ) :600-602.
4Fischer M, Hamm H, Werbelauer J, Sever drug-related skin reaction: toxic epidermal necrolysis caused by carbamazepine[J]. Klin Padiatr, 2004, 216(5) : 288-293.
5Campione E, Marulli Gc, Carrozzo AM, et al. High-dose intravenous immunoglobulin for severe drug reaction: efficacy in TEN [J]. Acta Derm Venereol, 2003, 83(6) : 430-432.
6Gareia-Doval I, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death?[J]. Arch Dermatol, 2000, 136(3): 323-327.
8Chave TA, Mortimer N J, Sladden M J, et al. Toxic epidermal necrolysis: current evidence, practical management and future Directions[J]. Br J Dermatol, 2005, 153(2): 241-253.
9Dalli RL, Kumar R, Kennedy P, et al. Toxic epidermal necrolysis/Stevens-Johnson syndrome: current trends in Management[J]. ANZ J Surg, 2007, 77(8): 671-676.
10Paquet P, Pierard GE, Quatresooz P. Novel treatments for druginduced toxic epidermal necrolysis (Lyell's syndrome) [J]. Int Arch Allergy Immunol, 2005, 136(3): 205-216.
